Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mayer Fishman

Showing results (1-10 of 69) with videos related to

Pageof 7
Sort By:
Methods in Molecular Biology (Clifton, N.J.)|March 13, 2014
Challenges facing the development of cancer vaccinesMayer Fishman
Clinical Advances in Hematology & Oncology : H&O|February 18, 2011
Review: therapy for kidney cancer with a sarcomatoid componentMayer Fishman
Expert Opinion on Biological Therapy|November 18, 2009
A changing world for DCvax: a PSMA loaded autologous dendritic cell vaccine for prostate cancerMayer Fishman
Translational Andrology and Urology|December 7, 2019
Commentary: 2-year follow up of pembrolizumab as second-line therapy for advanced urothelial cancer ("KEYNOTE 045")Mayer Fishman
Lancet (London, England)|February 28, 2004
Specific antitumour vaccine for renal cancerMayer Fishman, Scott Antonia
Current Oncology Reports|January 19, 2011
Sipuleucel-T: Prototype for development of anti-tumor vaccinesEstrella Carballido, Mayer Fishman
Journal of Immunotherapy (Hagerstown, Md. : 1997)|March 7, 2014
Regression of metastatic clear cell kidney cancer with interleukin-2 treatment following nivolumab (anti-PD-1) treatmentJason Brayer, Mayer Fishman
Cancer Control : Journal of the Moffitt Cancer Center|September 14, 2002
Immunotherapy of metastatic renal cell cancerMayer Fishman, John Seigne
Expert Opinion on Pharmacotherapy|November 22, 2011
Progress and contrasts of the development of tivozanib for therapy of kidney cancerShilpa Gupta, Mayer Fishman
Journal of the National Comprehensive Cancer Network : JNCCN|October 10, 2009
Management of metastatic renal cancerPatricia Thompson, Mayer Fishman
Pageof 7

Showing results (1-10 of 69) with videos related to

Sort By:
Pageof 7
Methods in Molecular Biology (Clifton, N.J.)|March 13, 2014
Challenges facing the development of cancer vaccinesMayer Fishman
Clinical Advances in Hematology & Oncology : H&O|February 18, 2011
Review: therapy for kidney cancer with a sarcomatoid componentMayer Fishman
Expert Opinion on Biological Therapy|November 18, 2009
A changing world for DCvax: a PSMA loaded autologous dendritic cell vaccine for prostate cancerMayer Fishman
Translational Andrology and Urology|December 7, 2019
Commentary: 2-year follow up of pembrolizumab as second-line therapy for advanced urothelial cancer ("KEYNOTE 045")Mayer Fishman
Lancet (London, England)|February 28, 2004
Specific antitumour vaccine for renal cancerMayer Fishman, Scott Antonia
Current Oncology Reports|January 19, 2011
Sipuleucel-T: Prototype for development of anti-tumor vaccinesEstrella Carballido, Mayer Fishman
Journal of Immunotherapy (Hagerstown, Md. : 1997)|March 7, 2014
Regression of metastatic clear cell kidney cancer with interleukin-2 treatment following nivolumab (anti-PD-1) treatmentJason Brayer, Mayer Fishman
Cancer Control : Journal of the Moffitt Cancer Center|September 14, 2002
Immunotherapy of metastatic renal cell cancerMayer Fishman, John Seigne
Expert Opinion on Pharmacotherapy|November 22, 2011
Progress and contrasts of the development of tivozanib for therapy of kidney cancerShilpa Gupta, Mayer Fishman
Journal of the National Comprehensive Cancer Network : JNCCN|October 10, 2009
Management of metastatic renal cancerPatricia Thompson, Mayer Fishman
Pageof 7